VISEN Pharmaceuticals disclosed that it bought back 8,500 ordinary shares on 05 June 2026 via on-market transactions. The shares were repurchased at prices ranging from HKD 20.20 to HKD 21.00, with an aggregated consideration of HKD 175,056 (approximately 0.18 million). The volume-weighted average price for the batch was HKD 20.59 per share.

Following the transaction, the company’s issued share capital (excluding treasury shares) fell from 113,843,664 to 113,835,164, while total issued shares remained unchanged at 113,926,864. Treasury shares increased to 91,700, all of which are being held rather than cancelled.

The repurchase forms part of a mandate approved on 27 June 2025 that authorises VISEN Pharma-B to buy back up to 11,392,686 shares. Cumulative repurchases under this mandate now stand at 91,700 shares, representing 0.08% of the issued share base when the mandate was granted; 11.30 million shares remain available for future buybacks.

Under Hong Kong listing rules, the company is subject to a moratorium on new share issues or sales of treasury shares until 05 July 2026. The board confirmed that all repurchases complied with the Main Board Listing Rules and relevant regulatory requirements.